Akebia merger with Keryx strategically positive, says Mizuho

Mizuho analyst Difei Yang likes Akebia Therapeutics’ (AKBA) merger with Keryx Biopharmaceuticals (KERX) from a “strategic and financial standpoint over time.” The companies’ products are complementary and will provide multiple avenues of value creation for the “new” Akebia, Yang tells investors in a research note. The analyst lowered his price target for Akebia to $21 from $24 and keeps a Buy rating on the shares

https://bit.ly/2tSSe0x